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Clinical resistance to the currently recommended extended-spectrum cephalosporins (ESCs), the last remaining treatment op-
tions for gonorrhea, is being reported. Gonorrhea may become untreatable, and new treatment options are crucial. We investi-
gated the in vitro activity of ertapenem, relative to ceftriaxone, againstN. gonorrhoeae isolates and the effects of ESC resistance
determinants on ertapenem. MICs were determined using agar dilution technique or Etest for international reference strains
(n 17) and clinicalN. gonorrhoeae isolates (n 257), which included the two extensively drug-resistant (XDR) strains H041
and F89 and additional isolates with high ESCMICs, clinical ESC resistance, and other types of clinical high-level andmultidrug
resistance (MDR). Genetic resistance determinants for ESCs (penA,mtrR, and penB) were sequenced. In general, the MICs of
ertapenem (MIC50 0.032g/ml; MIC90 0.064g/ml) paralleled those of ceftriaxone (MIC50 0.032g/ml; MIC90 0.125
g/ml). The ESC resistance determinants mainly increased the ertapenemMIC and ceftriaxoneMIC at similar levels. However,
the MIC ranges for ertapenem (0.002 to 0.125g/ml) and ceftriaxone (<0.002 to 4g/ml) differed, and the four (1.5%) ceftriax-
one-resistant isolates (MIC 0.5 to 4g/ml) had ertapenemMICs of 0.016 to 0.064g/ml. Accordingly, ertapenem had in vitro
advantages over ceftriaxone for isolates with ceftriaxone resistance. These in vitro results suggest that ertapenemmight be an
effective treatment option for gonorrhea, particularly for the currently identified ESC-resistant cases and possibly in a dual anti-
microbial therapy regimen. However, further knowledge regarding the genetic determinants (and their evolution) conferring
resistance to both antimicrobials, and clear correlates between genetic and phenotypic laboratory parameters and clinical treat-
ment outcomes, is essential.
Gonorrhea (etiological agent,Neisseria gonorrhoeae) remains amajor public health concern. In 2005, the World Health Or-
ganization (WHO) estimated 88 million gonorrhea cases among
adults globally, which placed this infection as the second most
prevalent bacterial sexually transmitted infection (59). Resistance
of N. gonorrhoeae to previously recommended first-line antimi-
crobials for treatment of gonorrhea is prevalent worldwide. Dur-
ing the last decade, the susceptibility to the extended-spectrum
cephalosporins (ESCs) cefixime (oral) and ceftriaxone (paren-
teral), the current first-line antimicrobials in most countries, has
decreased rapidly globally (3, 6, 8, 12, 16, 21, 22, 24, 29, 31, 39, 41,
52, 57, 58). Clinical failures with cefixime have also been verified
in Japan since 2003 (14, 60) and, more recently, in European
countries such as Austria (50), Norway (51), and theUnited King-
dom (18). Accordingly, ceftriaxone is essentially the last remain-
ing treatment option and, worryingly, there have also been a few
cases of confirmed failure treating pharyngeal gonorrhea with
ceftriaxone in Australia (44) and in Sweden (48). These cases,
however, likely also reflect that pharyngeal gonorrhea is harder to
treat than urogenital gonorrhea (3, 5, 31, 41, 58). Recently, and of
grave concern, the two first extensively drug-resistant (XDR [41])
gonococcal strains, H041 (32, 33) and F89 (49), which have been
confirmed to have high-level resistance to ceftriaxone, were de-
scribed. If these strains spread locally, nationally, or globally, gon-
orrhea may become untreatable in certain circumstances and in
the affected settings (32, 41, 49, 52). Consequently, for effective
future treatment of gonorrhea, it is imperative to promptly de-
velop new treatment strategies and, in particular, new treatment
options.
Disquietingly, there are few promising new antimicrobials or
other bactericidal compounds for treatment of gonorrhea in sight
(6, 24, 31, 32, 41, 49, 58). In this context, the present study inves-
tigated the in vitro activity of ertapenem, a parenteral 1--methyl-
carbapenem, against N. gonorrhoeae. Ertapenem shares activity
with other carbapenems such as imipenem and meropenem
against most bacterial species; however, it is less active against
nonfermentative Gram-negative bacteria such as Pseudomonas
aeruginosa. It has been shown to be safe, well tolerated (few ad-
verse effects), and effective, also in comparison with ceftriaxone,
against urinary tract infections (2, 7, 13, 20, 27, 46). However, in
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regard to N. gonorrhoeae, ertapenem has been evaluated only in
vitro and was compared to ceftriaxone solely in a sample of gono-
cocci with low ceftriaxoneMICs (maximumof 0.032g/ml) (26).
Accordingly, N. gonorrhoeae isolates for which ceftriaxone has
highMICvalues have not yet been tested for ertapenem resistance.
Similar resistance mechanisms have been shown to affect the
MICs of many -lactam antimicrobials, such as penicillins, nar-
row-spectrumcephalosporins, andESCs. Themainmechanism in
N. gonorrhoeae for decreased susceptibility and resistance to ESCs
is alteration of the penA gene encoding the lethal target, penicillin-
binding protein 2 (PBP2). Thus, acquisition of a penA mosaic
allele or single amino acid alterations of A501 or possibly G545
and P551 in PBP2 result in a lower affinity for ESCs (1, 16, 18, 19,
23, 25, 32, 38, 43, 45, 48–51, 55, 56, 62).Mutations in the promoter
and/or coding sequence ofmtrR result in the overexpression of the
MtrC-MtrD-MtrE efflux pump (mtrR resistance determinant),
which further increases the MICs of ESCs (16, 17, 23, 25, 32, 37,
48–51, 54, 61, 62), and porB1b mutations that alter amino acid
G101 and A102 in the PorB1b porin (the penB resistance determi-
nant) result in additionally increasedMICs of ESCs (16, 23, 25, 32,
34, 35, 37, 48–51, 62). At least one nontransformable resistance
determinant remains unknown (16, 25, 32, 45, 62). The effects of
ESC resistance determinants on the-lactam antimicrobial ertap-
enem are unknown.
In the present study, the in vitro activity of the carbapenem
ertapenem was compared to the activity of ceftriaxone against N.
gonorrhoeae, and the effects of ESC resistance determinants on
ertapenem were investigated. The examined N. gonorrhoeae iso-
lates and international reference strains included the only two
confirmed XDR strains, H041 (32, 33) and F89 (49), and addi-
tional isolates with substantially increased ESCMICs, clinical ESC
resistance, and other types of clinical high-level and multidrug
resistance (MDR).
MATERIALS AND METHODS
Neisseria gonorrhoeae isolates. A total of 126 N. gonorrhoeae clinical
isolates referred to theWHOCollaborating Centre (CC) for STD, Sydney,
Australia, 131N. gonorrhoeae clinical isolates referred to theWHOCC for
Gonorrhoea and other STIs, O¨rebro, Sweden, and 17 N. gonorrhoeae in-
ternational reference strains were examined. Some of these clinical gono-
coccal isolates have been included in previous studies (16, 25, 55), exam-
ining their susceptibility to ceftriaxone and their penA gene allele. The
clinical isolates were obtained from 2002 to 2011 and were selected to
represent geographically (mainly global representativeness), phenotypi-
cally, and genetically diverse isolates. Thus, the collection included the
XDRH041 strain from Japan (32, 33) and theXDRF89 strain fromFrance
(49) with clinical high-level resistance to all ESCs, many additional iso-
lates with substantially increasedMICs of ESCs, isolates displaying clinical
ESC resistance and associated with treatment failure (n 4 [48, 50, 51]),
and isolates with other types of clinical high-level resistance and/orMDR.
The international reference strains included the WHO A-E, WHO I,
WHO J, MS-11, and FA1090 gonococcal strains, as well as the recently
describedWHO2008N. gonorrhoeae reference strains (n 8) (47). These
WHO 2008 reference strains were also used for standardization of the
MIC testing in the two WHO CCs (based on giving highly comparable
results) as well as forming part of the quality control in all MIC testing.
The species of all gonococcal isolates and reference strains were initially
verified with a sugar utilization test and/or Phadebact GC Monoclonal
Test (Bactus AB, Sweden), and then the isolates were stored at70°C as
previously described (53). Prior to the MIC testing, the isolates were cul-
tured on modified Thayer-Martin culture media without any included
antimicrobials.
MIC determination.MIC determinations (inmicrograms per millili-
ter) using the agar dilution technique for ertapenem and ceftriaxone (126
clinical isolates examined in Sydney, Australia) were performed as previ-
ously described (40, 42) and with the Etest method for ertapenem and
ceftriaxone (131 clinical isolates and 17 international reference strains
examined in O¨rebro, Sweden) according to the manufacturer’s instruc-
tions (AB bioMérieux, Solna, Sweden) and as previously described (4).
The MIC testing for each isolate was performed in parallel for both anti-
microbials. -Lactamase activity was detected using nitrocefin discs.
For ceftriaxone, interpretative criteria from the Clinical and Labora-
tory Standards Institute (CLSI [11]) were used. No interpretative criteria
have been stated by CLSI (11) or any other organization for ertapenem.
Genetic characterization. Molecular epidemiological characteriza-
tion of all clinical isolates and reference strains bymeans ofN. gonorrhoeae
multiantigen sequence typing (NG-MAST) was performed as described
previously (28, 53). PCR amplification and sequencing of known gono-
coccal ESC resistance determinants, i.e., penA, mtrR, and porB1b, were
done as described elsewhere (25, 47, 55).
RESULTS
In vitro activity of ertapenem, compared to ceftriaxone, against
Neisseria gonorrhoeae clinical isolates (n  257) and interna-
tional reference strains (n 17). In general, the MICs of ertap-
enem (MIC50, 0.032 g/ml; MIC90, 0.064 g/ml) and ceftriaxone
(MIC50, 0.032 g/ml; MIC90, 0.125 g/ml) were similar. For the
-lactamase-producing isolates (n 23), the MICs of ertapenem
(MIC50, 0.016 g/ml; MIC90, 0.032 g/ml) and ceftriaxone
(MIC50, 0.032 g/ml; MIC90, 0.064 g/ml) were also similar.
However, the ranges of MIC values for ertapenem (0.002 to 0.125
g/ml) and ceftriaxone (0.002 to 4g/ml) substantially differed
(Fig. 1).
Four (1.5%) isolates were resistant to ceftriaxone (MIC, 0.5 to
4g/ml) according to the interpretative criteria stated by theCLSI
(11), but these isolates showed MICs from 0.016 g/ml to 0.064
g/ml only for ertapenem. For the XDR N. gonorrhoeae strains
H041 (32, 33) and F89 (49), both of which are highly resistant to
cefixime (MIC  4 to 8 g/ml) and ceftriaxone (MIC  2 to 4
g/ml), the ertapenem MICs were significantly lower (0.064
g/ml and 0.016 g/ml, respectively). Furthermore, for the
strains causing cefixime treatment failures in Norway (n  2;
MIC, 0.125 g/ml and 0.25 to 0.5 g/ml for ceftriaxone and ce-
fixime, respectively [51]) and in Austria (n  1; MIC, 0.5 g/ml
and 1.0g/ml for ceftriaxone and cefixime, respectively [50]) and
a ceftriaxone treatment failure strain from a case of pharyngeal
gonorrhea in Sweden (n  1; MIC, 0.125 to 0.25 g/ml and 0.5
g/ml for ceftriaxone and cefixime, respectively [48]), the corre-
spondingMIC values for ertapenem were lower, ranging between
0.064 and 0.125 g/ml.
Effects ofESCresistancedeterminantsonertapeneminNeis-
seria gonorrhoeae clinical isolates (n  257) and international
reference strains (n 17). Similarmechanisms affect theMICs of
many -lactam antimicrobials; however, the effects of ESC resis-
tance determinants, such as specific penA, mtrR, or penB altera-
tions, on ertapenem resistance are unknown. Of the 274 N. gon-
orrhoeae isolates, 101 (36.9%), 71 (25.9%), 242 (88.3%), and 249
(90.9%) had a penAmosaic allele, an alteration of A501 in PBP2,
an mtrR resistance determinant, and a penB resistance determi-
nant, respectively (Table 1). The presence of, in particular, a penA
mosaic allele was associated with increased MICs of ertapenem;
e.g., 25 (35.7%), 48 (50.5%), and 21 (91.3%) of all the isolates with
an ertapenemMICof 0.032g/ml, 0.064g/ml, and 0.125g/ml,
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respectively, contained a penAmosaic allele. For comparison, only
seven (8.1%) of the isolates with an ertapenem MIC  0.032
g/ml contained a penA mosaic allele (Table 1 and Fig. 2). Fur-
thermore, the isolates containing a penA mosaic allele and, addi-
tionally, themtrR and penB resistance determinants had the high-
est ertapenemMICs. Nevertheless, the specific penAmosaic alleles
resulting in ceftriaxone resistance in four isolates (ceftriaxone
MIC, 0.5 to 4 g/ml) caused a significantly lower MIC of ertap-
enem, ranging from 0.016 to 0.064 (Table 1). In comparison with
the penA mosaic alleles, the alteration of A501 in PBP2 appeared
less associatedwith increasedMICs of ertapenem (Table 1 and Fig.
2). In fact, isolates containing both the mtrR resistance determi-
nant and penB resistance determinant, combined with a penA
wild-type allele, displayed MICs of ertapenem as high as those
seenwith the isolates additionally containing an alteration ofA501
in PBP2 (Table 1).
Molecular epidemiological characterization of examined
Neisseria gonorrhoeae clinical isolates (n  257) and interna-
tional reference strains (n 17). In total, the examined N. gon-
orrhoeae isolates were assigned to 133 different NG-MAST se-
quence types. ST225 (17 isolates), which is an internationally
transmitted clone associatedwith resistance to ciprofloxacin and a
slightly increasedMIC of ceftriaxone, and ST1407 (n 33), com-
prising a globally spread clone that accounts for a substantial pro-
portion of the isolates showing intermediate susceptibility and
resistance to ESCs and MDR internationally (16, 18, 43, 49–51),
were the most prevalent sequence types. Among the sequence
types represented by more than five isolates (n 8), ST1407 (n
33;MIC50, 0.064g/ml), ST5 (n 8;MIC50, 0.064g/ml), ST326
(n  7; MIC50, 0.125 g/ml), and ST925 (n  6; MIC50, 0.125
g/ml) appeared to be associated with increased MICs of ertap-
enem. Each of these sequence type clones contained themtrR de-
terminant and penB determinant, and all sequence types, with
exception of ST5, contained also a penAmosaic allele.
DISCUSSION
This is the first study investigating the in vitro activity of the car-
bapenem ertapenem relative to ceftriaxone against ESC-suscepti-
ble and ESC-resistant N. gonorrhoeae isolates, as well as outlining
the effects of ESC resistance determinants on ertapenem. Gono-
coccal strains from a collection representing geographically and
genetically diverse isolates were examined. The collection in-
cluded the only two confirmed XDR strains, H041 (32, 33) and
F89 (49), and additional isolates with substantially increased ESC
MICs, ESC resistance associated with ESC treatment failure, and
other types of clinical MDR. Ertapenem had no apparent in vitro
advantage over ceftriaxone for N. gonorrhoeae isolates with lower
ceftriaxone MICs. This is also in full concordance with a previous
study by Livermore et al. (26), where ceftriaxone retained superior
in vitro activity, compared to ertapenem, against gonococcal iso-
lates with lower ceftriaxone MICs. Nevertheless, for all isolates
with resistance to ceftriaxone (MIC, 0.5 to 4 g/ml), the corre-
sponding MICs of ertapenem were low (0.016 to 0.064 g/ml).
Ertapenem was also highly active against isolates with high-level
clinical resistance and MDR to all types of other antimicrobials
(data not shown). Accordingly, ertapenem may be an effective
treatment option for gonorrhea and, in particular, for the cur-
rently identified ESC-resistant cases and possibly in dual antimi-
crobial therapy for treatment of gonorrhea.
Ertapenem is rapidly bactericidal and, like other -lactam an-
timicrobials, derives its activity from binding to specific PBPs and
subsequent blocking of cell wall synthesis that result in time-de-
pendent killing. Resistance to ertapenem in bacteria is usuallyme-
diated by upregulation of efflux pumps, porin deficiency, produc-
tion of metallo--lactamases/carbapenemases, or PBP changes
resulting in decreased affinity for the drug. Ertapenem activity
may also be affected by some classical extended-spectrum -lac-
tamases (ESBL) and hyperproduced AmpC -lactamases, but the
organisms mainly remain clinically susceptible. Nevertheless, re-
sistance can arise when these enzymes are presented with extreme
impermeability (7, 13, 27). In the present study, for N. gonor-
rhoeae isolates with increased MICs of ceftriaxone (but not full
resistance), the penA mosaic alleles encoding mosaic PBP2s with
less affinity for ESCs appeared to increase theMICof ertapenem to
a level similar to that of ceftriaxone. For these penA mosaic iso-
lates, the MIC of ertapenem appeared to further increase also
FIG 1 MIC (micrograms per milliliter) distribution of ertapenem and ceftriaxone for clinical Neisseria gonorrhoeae isolates (n  257) and N. gonorrhoeae
international reference strains (n 17).
Activity of Ertapenem against N. gonorrhoeae
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when, in addition, the mtrR and penB resistance determinants
resulting in increased efflux and decreased intake of the antimi-
crobials, respectively, were present. However, for N. gonorrhoeae
isolates with highMIC values (clinical ceftriaxone resistance), the
MICs of ertapenem remained relatively low despite the presence
of a penA mosaic allele combined with the mtrR and penB resis-
tance determinants. Thus, the specific penA mosaic alleles that
evidently result in clinical resistance to ceftriaxone resulted in low
ertapenemMIC values, ranging from 0.016g/ml to 0.064g/ml.
Nevertheless, novel penAmosaic alleles are continuously evolving,
and, depending on their sequences, these may substantially affect
also the MIC of ertapenem. Therefore, further knowledge regard-
ing the genetic resistance determinants, in particular, the effects of
different penA mosaic alleles and other penA alterations, and the
implications of the emergence and evolution of these for both
ceftriaxone and ertapenem are of paramount importance. Finally,
the future possibility of acquisition of a carbapenemase or a
TEM-1 -lactamase that evolves into an ESBL, which degrades
ertapenem, inN. gonorrhoeae cannot be excluded, especially when
the blaTEM-1 gene appears to be evolving (30).
For future treatment of gonorrhea, the development of new
treatment regimens and/or options is essential. Use of an in-
creased dose of ceftriaxone has already been implemented (9, 14,
41). However, this approach provides only a short-term solution.
Dual antimicrobial combination treatment has also recently been
introduced in the United States (58) and the United Kingdom (5)
for uncomplicated anogenital gonorrhea cases. Unfortunately,
due to cost issues, combination therapy is challenging in settings
of lesser resources and, froma global public health perspective, the
need for an effective antimicrobial for single-drug treatment of
gonorrhea appears fundamental. However, for future treatment
of gonorrhea, there are few promising novel alternatives in sight
(6, 24, 31, 32, 41, 49, 58). Nevertheless, gentamicin has been used
as a first-line treatment in Malawi, Africa, for nearly 2 decades
without any reported emergence of in vitro resistance, and in vitro
susceptibility in the European Union appears high (10). Further-
more, a new fluoroketolide, solithromycin (CEM-101), has also
been shown to have high in vitro activity against gonococci (15,
36). Finally, the present report shows that ertapenemmay also be
an effective option for treatment of gonorrhea, in particular, for
TABLE 1 MICs of ertapenem and ceftriaxone, and presence of determinants of resistance to extended-spectrum cephalosporins, for N. gonorrhoeae
clinical isolates (n 257) and international reference strains (n 17)
Cephalosporin resistance mechanism(s)
No. (%) of isolates with MIC (g/ml) ofa:
0.002 0.004 0.008 0.016 0.032 0.064 0.125 0.25 0.5 1 2 4
penAmosaicb isolates (n 101)
penAmosaicbmtrRc TX 3 (1.1) 1 (0.4)
ETP 2 (0.7) 2 (0.7)
penAmosaicb penBd TX 2 (0.7)
ETP 2 (0.7)
penAmosaicbmtrRc penBd TX 2 (0.7) 6 (2.2) 22 (8.0) 28 (10) 30 (11) 3 (1.1) 1 (0.4) 1 (0.4) 2 (0.7)
ETP 1 (0.4) 3 (1.1) 3 (1.1) 23 (8.4) 44 (16) 21 (7.7)
penA A501-altered isolates (n 70)
penA A501Ve TX 1 (0.4)
ETP 1 (0.4)
penA A501VemtrRc TX 1 (0.4)
ETP 1 (0.4)
penA A501Ve penBd TX 3 (1.1)
ETP 1 (0.4) 2 (0.7)
penA A501V/TemtrRc penBd TX 1 (0.4) 3 (1.1) 11 (4.0) 33 (12) 17 (6.2)
ETP 1 (0.4) 11 (4.0) 17 (6.2) 16 (5.8) 19 (6.9) 1 (0.4)
Isolates with other penA (n 103)
mtrRc penBd TX 2 (0.7) 8 (2.9) 5 (1.8) 13 (4.7) 30 (11) 14 (5.1) 1 (0.4)
ETP 13 (4.7) 9 (3.3) 23 (8.4) 27 (9.8) 1 (0.4)
mtrRc TX 1 (0.4) 3 (1.1)
ETP 1 (0.4) 1 (0.4) 2 (0.7)
penBd TX 4 (1.4) 4 (1.4) 1 (0.4) 2 (0.7)
ETP 1 (0.4) 3 (1.1) 4 (1.4) 2 (0.7) 1 (0.4)
Wild type TX 5 (1.8) 6 (2.2) 1 (0.4) 1 (0.4) 1 (0.4) 1 (0.4)
ETP 1 (0.4) 5 (1.8) 5 (1.8) 2 (0.7) 2 (0.7)
Total TX 11 (3.9) 20 (7.3) 15 (5.5) 25 (9.1) 71 (30) 77 (28) 48 (18) 3 (1.1) 1 (0.4) 1 (0.4) 2 (0.7)
ETP 2 (0.8) 10 (3.7) 37 (14) 36 (13) 70 (25) 95 (34) 23 (8.5)
a Only whole MIC dilutions are presented. TX, ceftriaxone; ETP, ertapenem.
b penAmosaic, mosaic alleles, which may differ in their exact nucleotide sequences, encoding a mosaic penicillin binding protein 2 (PBP2), which causes decreased susceptibility to
extended-spectrum cephalosporins.
c Characteristic single nucleotide (A) deletion in the inverted repeat of the promoter region ofmtrR that causes overexpression of the MtrCDE efflux pump, which results in a
further decreased susceptibility to extended-spectrum cephalosporins.
d Alterations of amino acids 120 and/or 121 in the porin PorB1b that cause a decreased intake of extended-spectrum cephalosporins and, accordingly, a further decreased
susceptibility to extended-spectrum cephalosporins.
e Alterations of amino acid A501 in PBP2, which has been associated with decreased susceptibility to extended-spectrum cephalosporins.
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currently identified ESC-resistant cases and possibly in a dual an-
timicrobial combination therapy regimen. However, all these po-
tential future treatment regimens require up-to-date and compre-
hensive in vitro and in vivo evaluations, including appropriately
designed, randomized, and controlled treatment studies (evaluat-
ing parameters such as efficacy, safety, toxicity, and cost) and
pharmacokinetic/pharmacodynamics data for genital and extra-
genital (especially pharyngeal) gonorrhea. Furthermore, addi-
tional knowledge regarding present and future (in vitro-selected
and in vivo-emergent) genetic resistance determinants for these
antimicrobials, and clear correlates between genetic and pheno-
typic laboratory parameters and clinical treatment outcomes,
would be very valuable.
In conclusion, clinical resistance to ceftriaxone in N. gonor-
rhoeae has been reported and the widespread concern that gonor-
rhea may become untreatable in certain circumstances is valid. A
major global focus, imperative for public health, is to promptly
identify new antimicrobials (or other compounds) for the effec-
tive treatment of gonorrhea. The present in vitro study showed
that ertapenem may be an effective treatment option for gonor-
rhea and, particularly, for the currently identified ESC-resistant
cases and possibly as part of a dual antimicrobial therapy regimen.
Additional appropriately designed in vitro and surveillance studies
and, in particular, in vivo clinical efficacy trials for all potentially
new therapeutic options for gonorrhea are urgently needed.
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